Planet 13 Holdings Inc. announced a partnership with Praetorian Global to bring ONI’s Private Stock line of solventless concentrates to its Florida dispensaries. The All‑in‑One Solventless Hash Rosin Vapes will be available at all Planet 13 Florida locations beginning November 21, 2025, with the Cold Cure Rosin slated for a January 2026 launch.
The move comes as Florida remains the company’s fastest‑growing market. Planet 13 has recently exited California to focus resources on Nevada and Florida, where it enjoys a stronger competitive position and higher margins. The partnership is part of a broader strategy to improve operating leverage and reduce the cash drain that California’s high‑cost environment had imposed.
Planet 13’s Q3 2025 results showed a 27.6% year‑over‑year revenue decline to $23.3 million and a net loss of $44.0 million, largely driven by a one‑time impairment charge. Management described the quarter as a “low point” but highlighted significant cost‑cutting initiatives that reduced SG&A and positioned the company for a rebound in Q4. The new ONI line is expected to help lift revenue and improve gross margin by adding a high‑margin, premium product that aligns with consumer demand for solventless concentrates.
All‑in‑One Solventless Hash Rosin Vapes combine ONI’s legacy genetics with precision extraction, offering a product that appeals to both medical patients and recreational users seeking clean, potent concentrates. The Cold Cure Rosin, a low‑temperature extraction that preserves terpene profiles, will further diversify Planet 13’s concentrate portfolio and reinforce its premium positioning in Florida’s competitive market.
Jeffrey Trappe, Chief Operating Officer of Planet 13 Florida, said, “We’re excited to introduce ONI’s Private Stock line to Florida. ONI’s legacy of precision and purity fits perfectly with Planet 13’s commitment to offering patients the highest‑quality, most innovative products available.” Co‑CEO Larry Scheffler added, “The partnership signals that we’re turning the corner on margin improvement and that our focus on core markets is paying off.”
The launch is expected to strengthen Planet 13’s competitive advantage in Florida, where patient demand for high‑quality concentrates is rising. By adding a premium, solventless line, the company can capture a larger share of the high‑margin segment, support its margin‑improvement goals, and position itself for stronger growth in 2026 as the BHO lab comes online and operational efficiencies take hold.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.